Form 4: Axogen Director Kathy Weiler Reports Acquisition of Shares and Stock Options

Director Kathy Weiler reports acquisition of Axogen shares and stock options as part of annual equity grant.

Summary

• Kathy Weiler, a director of Axogen, Inc., reported the acquisition of 10,653 shares of common stock and 18,248 employee stock options on June 6, 2024.
• The acquisition of common stock is related to restricted stock units.
• The stock options have an exercise price of $7.04 and expire on June 6, 2034.
• These transactions are part of her annual equity grant for service as a Director on the Axogen, Inc. Board of Directors.
• The equity grant is valued at $150,000 as of the grant date and vests on June 6, 2025.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and alignment of interests.

Positives

• The acquisition of shares and stock options reflects continued alignment of the director's interests with those of the company and its shareholders.

Industry Context

This filing is a routine disclosure related to director compensation and equity ownership, common in publicly traded companies.

Comparison to Industry Standards

• Director compensation packages, including stock options and restricted stock units, are standard practice in publicly traded companies like Axogen.
• The valuation and vesting schedules are typical for director equity grants, aligning with industry norms for incentivizing long-term performance and commitment.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates